Dai-Dan (TSE:1980) Stock Price Reflects Softer EPS Despite Fair Value Gap

Dai-Dan came into this print with a reputation for steady profit growth and a stock that looked cheap against a discounted cash flow estimate, yet the price sat at ¥2,659 after a flat week and a weak 3 month run. The headline from Q1 2027 is a cooling in earnings power rather than a collapse. Basic earnings per share of ¥50.78 and net income of ¥6,571m now sit against a 13x P/E and a share price still below that implied fair value, which keeps the gap between expectation and current reality very much open.

Is Dai-Dan a straightforward value opportunity at a 13x P/E, or is that 24.5% gap to the DCF estimate sending a different message about the stock? Compare the current price, implied fair value, and earnings power in our valuation analysis for Dai-Dan.

Q1 2027 Earnings Summary

• Revenue Q1 2027 vs. Q1 2026: ¥61,601m vs. ¥60,147m (relatively stable year on year with a modest uptick)
• Net Income Q1 2027 vs. Q1 2026: ¥6,571m vs. ¥6,885m (slight softening in quarterly profit)
• Basic EPS Q1 2027 vs. Q1 2026: ¥50.78 vs. ¥53.51 (marginal decline in earnings per share)
• Trailing 12M Net Margin FY Q1 2027 vs. FY Q1 2026: 10.3% vs. 8.3% (improved profitability over the last year)

Prefer clean visuals instead of another dense wall of figures and PDF pages? View a full picture of Dai-Dan, with its valuation laid out in simple charts, through our company report for Dai-Dan.

Dai-Dan’s Healthcare Angle And Earnings Resilience

Dai-Dan markets itself as more than a typical contractor, with a strong tilt toward healthcare and clean environment projects. The latest quarter broadly echoes that profile. Revenue of ¥61,601m is close to last year’s level and net income of ¥6,571m remains solid in absolute terms. The trailing 12 month net margin of 10.3% versus 8.3% a year earlier supports the idea that higher spec work can sustain healthier profitability. For investors leaning toward the healthcare and clean room story, these figures keep a constructive case intact rather than breaking it.

Where The Dai-Dan Bear Case Still Bites

The cautious view on Dai-Dan often focuses on project based cyclicality and margin pressure. The current numbers do not fully close that chapter. Revenue is only slightly above last year and quarterly net income and EPS are a little softer. That mix will remind you that earnings can ebb even when sales are steady. Recent 30 day and 90 day share price declines near 9% and 11% also show how quickly sentiment can cool when growth momentum is questioned, even if trailing profitability ratios look healthier on paper.

Compare how Dai-Dan talks up its healthcare and clean environment focus with what the share price reset after Q1 is really telling you. See the consensus price target analysis for Dai-Dan to check whether analysts think this earnings resilience deserves a higher or lower target from here.

Stay Ahead With Simply Wall St

If Dai-Dan’s mix of healthcare projects, a 13x P/E and a share price sitting below an implied fair value has caught your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and spot a potential entry point. Once you decide to take a position, keep the noise down and the signal clear by managing your holdings through the Portfolio Command Center that highlights only the most important developments. For a longer term view, tap into what other investors are seeing and questioning through the Community to put your own thesis in context. By surfacing possible catalysts and risks early, Simply Wall St aims to help you monitor the market in a more proactive way, rather than reacting after the fact.

Seeking Fresh Alternatives Beyond Dai-Dan

Some stocks are already building breakout momentum while others are still under the radar for now. Spot fresh ideas before the crowd catches on and act now.

• Track sturdy balance sheets before they start flying by scanning the curated list of solid balance sheet and fundamentals stocks (40 results) that highlights companies investors may only notice much later.
• Review early income opportunities while yields still look appealing by using the hand picked 43 dividend fortresses, before these payouts are fully reflected in prices.
• Identify potential growth stories that others are still overlooking by scanning the carefully filtered 63 high quality undiscovered gems and consider them before broader interest develops.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com